Ingenol CAS 30220-46-3

2401120

Synonyms: (-)-Ingenol

50 mg € 240
100 mg € 340
250 mg € 620
500 mg € 1120
For bulk quantities contact us at [email protected]
Cat. No. NST-10-168
CAS 30220-46-3
Purity 98% (HPLC)
Plant Euphorbia spp
Appearance White Powder
Molecular formula C20H26O5
Molecular weight 348,19
Storage +2 … +8 °C

Certificate of analysis available by request to [email protected]

SKU: N/A Categories: ,
Description

Ingenol: Harnessing Nature’s Potent Diterpene

1. Molecular Identity

  • Chemical Name: (1aR,2S,5R,5aS,6S,8aS,9R,10aS)-5,6,9-trihydroxy-4-methylene-1,1,7,10a-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-methanocyclopenta[a]cyclopropa[e]cyclodecen-6-yl acetate
  • CAS Number: 30220-46-3
  • Source: Derived from various Euphorbia species, notably Euphorbia peplus

2. Biochemical Significance

Ingenol is a complex diterpene with a unique molecular structure that contributes to its potent biological activities. Its ability to modulate protein kinase C (PKC) and other cellular pathways makes it a compound of significant interest in biomedical research.

3. Key Therapeutic Properties

  • Anticancer: Demonstrates potential in treating various skin cancers
  • Immunomodulatory: Activates and regulates immune responses
  • Anti-inflammatory: Modulates inflammatory pathways
  • Antiviral: Shows promise against certain viral infections

4. Potential Applications

  • Topical treatment of actinic keratosis and skin cancers
  • Immunotherapy research
  • Anti-inflammatory drug development
  • Antiviral therapy investigations

5. Current Research Focus

Ongoing studies are investigating Ingenol’s effects on:

  • Various skin conditions and dermatological cancers
  • Immune system modulation in different disease states
  • Inflammatory disorders
  • Viral infections, particularly HIV latency

6. Formulation Challenges and Innovations

Researchers are actively working on:

  • Developing stable topical formulations
  • Enhancing systemic delivery for potential internal applications
  • Creating targeted delivery systems for specific tissues

7. Regulatory Considerations

Ingenol mebutate, a derivative of Ingenol (CAS CAS 30220-46-3), has been approved for topical treatment of actinic keratosis. Ongoing research aims to expand the therapeutic applications of Ingenol and its derivatives.

8. Future Directions

The scientific community anticipates:

  • Advanced clinical trials for various skin conditions
  • Development of novel Ingenol derivatives with enhanced properties
  • Exploration of Ingenol’s potential in systemic treatments

9. Collaborative Opportunities

We invite researchers, pharmaceutical companies, and healthcare professionals to explore the therapeutic potential of Ingenol. For inquiries, collaborations, or to discuss how Ingenol can benefit your research or product development, please contact us at [email protected].

Join us in unlocking the full potential of Ingenol – a powerful diterpene bridging natural product chemistry and innovative medical treatments.